Humacyte (HUMA) Projected to Post Quarterly Earnings on Friday

Key Points

• Humacyte is scheduled to report Q4 2025 results before the market opens on March 27, 2026, with analysts forecasting an EPS loss of ($0.13) and revenue of about $1.349M.
• The stock tumbled about 18.9%, opening at $0.86, trading near its 52-week low ($0.81) with a market cap of roughly $161M and a high leverage profile (debt-to-equity ~2.97).
• Wall Street sentiment is mixed but overall a Moderate Buy consensus with an average price target of $8.14 (seven Buy ratings, one Sell), and institutional investors hold about 44.7% of the shares amid recent stake increases by several firms.

Humacyte (NASDAQ:HUMA - Get Free Report) is expected to issue its Q4 2025 results before the market opens on Friday, March 27th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $1.3490 million for the quarter. Interested persons can check the company's upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 27, 2026 at 4:00 PM ET.

Humacyte Stock Down 18.9%

HUMA stock opened at $0.86 on Friday. Humacyte has a 52-week low of $0.81 and a 52-week high of $3.36. The company's 50 day simple moving average is $1.08 and its 200-day simple moving average is $1.31. The company has a debt-to-equity ratio of 2.97, a current ratio of 1.62 and a quick ratio of 0.90. The firm has a market capitalization of $161.05 million, a P/E ratio of -3.74 and a beta of 1.89.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Quadrature Capital Ltd acquired a new stake in shares of Humacyte during the 4th quarter valued at $201,000. Wells Fargo & Company MN increased its stake in shares of Humacyte by 78.0% in the fourth quarter. Wells Fargo & Company MN now owns 174,470 shares of the company's stock worth $168,000 after acquiring an additional 76,449 shares during the last quarter. BNP Paribas Financial Markets increased its stake in shares of Humacyte by 87.1% in the third quarter. BNP Paribas Financial Markets now owns 91,740 shares of the company's stock worth $160,000 after acquiring an additional 42,701 shares during the last quarter. Aristides Capital LLC purchased a new stake in shares of Humacyte during the fourth quarter worth $156,000. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Humacyte by 41.2% during the second quarter. The Manufacturers Life Insurance Company now owns 45,960 shares of the company's stock worth $96,000 after acquiring an additional 13,407 shares in the last quarter. Institutional investors and hedge funds own 44.71% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on HUMA. HC Wainwright reaffirmed a "buy" rating and issued a $3.00 price objective on shares of Humacyte in a research note on Monday, December 1st. Wall Street Zen lowered Humacyte from a "hold" rating to a "sell" rating in a report on Sunday, December 21st. UBS Group reaffirmed a "buy" rating on shares of Humacyte in a research report on Monday, December 1st. Benchmark lowered their price target on Humacyte from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, January 21st. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Humacyte in a research report on Monday, December 29th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Humacyte currently has a consensus rating of "Moderate Buy" and an average price target of $8.14.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company's proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient's own tissue. Humacyte's primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company's lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.